FDA Just Relaxed the Rules on “Wellness” Wearables—So Why Are Doctors Still Telling You Not to Trust Your Watch’s Blood Pressure?
The FDA is giving consumer wearables more room to make low-risk wellness claims—while drawing a hard line around blood pressure estimates. That boundary explains the whiplash patients feel and the caution clinicians keep repeating.
Key Points
- 1Understand the split: FDA’s 2026 wellness guidance expands enforcement discretion for low-risk claims, but it does not approve accuracy or clinical use.
- 2Follow the red line: FDA warned Sept. 16, 2025 against unauthorized smartwatch/ring blood pressure estimates due to misdiagnosis, treatment errors, and delayed care.
- 3Use wearables wisely: track trends and habits, then confirm high-stakes metrics like blood pressure with clinically appropriate, authorized measurement methods.
A patient comes in clutching a smartwatch screenshot like it’s a lab result. “My blood pressure was 150 over 95 all week,” they say. The clinician sighs—not because wearables are frivolous, but because blood pressure is the kind of number that can change a prescription, a diagnosis, or a life.
That tension is colliding with a second, quieter story: the U.S. Food and Drug Administration has, in fact, become more permissive about certain wellness features in consumer devices. On January 6, 2026, the agency issued a revised final guidance called “General Wellness: Policy for Low Risk Devices.” It reads, to many observers, like a green light for more sensor-based wellness wearables.
Then comes the apparent whiplash. Just months earlier—on September 16, 2025—the FDA published a safety communication telling consumers and clinicians: do not use unauthorized devices to measure or estimate blood pressure, including software features on smartwatches and smart rings. The agency warned that bad numbers can lead to dangerous choices.
Both things can be true. The FDA can loosen its grip on low-risk wellness features while drawing a bright red line around blood pressure. Understanding that line—where “wellness” ends and “medical device” begins—has become essential for anyone buying, wearing, or recommending health tech.
“The FDA can be flexible about wellness metrics and uncompromising about blood pressure—because the stakes are not the same.”
— — TheMurrow Editorial
What the FDA actually changed in 2026—and what it did not
On January 6, 2026, the FDA issued a revised final guidance titled “General Wellness: Policy for Low Risk Devices.” The key word is guidance. The document is nonbinding, meaning it does not create new legal requirements. It describes when the FDA intends to apply enforcement discretion—a compliance policy choice—toward certain products making general wellness claims.
That matters because many consumer devices sit in a gray zone. A product can look “medical” while being marketed as lifestyle: sleep scores, stress indicators, recovery readiness, heart-rate trends, prompts to move. Under the general wellness approach, the FDA may choose not to enforce device requirements for certain low-risk products with wellness-only claims.
Three specifics anchor what changed:
- Date and scope: The policy update is dated January 6, 2026, and it addresses a category called general wellness products.
- Non-approval: Guidance does not “approve” or “clear” a wearable. It does not certify the accuracy of a metric or its clinical usefulness.
- A legal backdrop: The FDA points to the 21st Century Cures Act, enacted December 13, 2016, which amended the law to exclude certain software functions (including some lifestyle/healthy-living functions) from the definition of a medical device.
Legal analysts read the 2026 revision as an expansion or clarification, particularly for sensor-enabled wearables—more room for devices that track physiological signals as long as the claims stay in the wellness lane. Foley & Lardner described the update as relaxing restrictions for wearables and related features, and McGuireWoods framed it as “more flexibility” for devices that qualify under the general wellness exception.
That nuance is the point. The FDA didn’t “open the gates” to medical-grade wearables. It clarified when it will step back from enforcement—when risks are low and claims are not medical.
“Nonbinding guidance isn’t a stamp of clinical credibility. It’s a description of when the FDA may choose not to intervene.”
— — TheMurrow Editorial
The key statistic hiding in plain sight: a decade-long arc
- December 13, 2016: the 21st Century Cures Act reshaped how certain software is treated.
- January 6, 2026: the FDA revised its general wellness policy.
That’s a nearly 10-year trajectory toward carving out space for low-risk consumer health features—without turning every fitness metric into a regulated medical device.
Why blood pressure triggers a different FDA response
On September 16, 2025, the FDA issued a stark safety communication: “Do Not Use Unauthorized Devices for Measuring Blood Pressure.” The warning explicitly includes software features on wearables such as smartwatches and smart rings that claim to measure or estimate blood pressure.
The agency’s reasoning is blunt. Inaccurate blood pressure values can lead to:
- misdiagnosis
- inappropriate treatment changes
- delayed medical care
The FDA spelled out what those errors can mean: stroke, heart attack, heart failure, kidney failure, cognitive decline, early death. That list is not rhetorical flourish; it’s the clinical risk profile of uncontrolled or mismanaged hypertension.
Crucially, the FDA also clarified a regulatory boundary: these blood pressure measurement or estimation tools do not fall under the general wellness policy. They are not intended solely for general wellness, and they are not considered low risk. Blood pressure is too tightly linked to disease decisions.
So while the 2026 guidance appears to broaden discretion for certain wellness wearables, the FDA has simultaneously told the public: don’t confuse “wellness-friendly” policy with permission to market medical claims—especially for blood pressure.
A “wellness” claim versus a “medical” claim, in practice
“Blood pressure is not a motivational metric; it’s a clinical decision point.”
— — TheMurrow Editorial
The WHOOP warning letter: a case study in where the line is drawn
On July 14, 2025, the FDA issued a warning letter to WHOOP, Inc., addressed to CEO Will Ahmed. The subject: WHOOP’s Blood Pressure Insights feature, which the agency said was marketed without FDA authorization.
The FDA’s rationale matters beyond WHOOP because it outlines a general regulatory logic. A feature that provides systolic/diastolic blood pressure estimations is “inherently associated” with diagnosing hypo- and hypertension. In other words, even if a company frames the feature as “insights” or “trends,” the nature of the output ties it to medical decision-making.
That interpretation is the opposite of a “general wellness” framing. A sleep score can be helpful without implying a disease diagnosis. A blood pressure estimate, by contrast, is strongly associated with a medical condition and can influence medication and care-seeking behavior.
The warning letter also helps decode why clinicians keep pushing back when patients say, “But my wearable said…” Regulatory lines and clinical lines aren’t identical, but for blood pressure they point in the same direction: caution.
A key statistic for readers: the timeline of escalation
- July 14, 2025: WHOOP warning letter over BP estimations.
- September 16, 2025: FDA safety communication: don’t use unauthorized BP devices.
- January 6, 2026: revised general wellness guidance—often read as broader flexibility, but not for BP.
That’s a six-month stretch in which the agency tightened around blood pressure while loosening elsewhere.
The science problem doctors can’t ignore: cuffless BP isn’t consistently reliable yet
In December 2025, the American Heart Association issued a scientific statement on cuffless blood pressure technologies. The AHA’s message was measured: these technologies show promise, but many personal wearables have not been proven accurate or reliable in real-world use.
Real-world use is the harsh test. Blood pressure changes with activity, sleep, stress, hydration, and medication timing. A measurement method that behaves in a lab can fall apart when someone is:
- exercising
- sleeping
- going about daily activity
- taking medications that affect blood pressure
The AHA emphasized the need for more research and standardized validation protocols before cuffless blood pressure can be used to diagnose. That’s a bright clinical line: a number that’s “interesting” is not the same as a number that justifies a diagnosis or a medication adjustment.
None of this means cuffless BP is a scam. It means the bar is high because the downstream consequences are serious. A small systematic error isn’t just a rounding issue; it can change whether someone is labeled hypertensive, whether they’re reassured when they shouldn’t be, or whether they’re treated when they don’t need to be.
A practical translation: why “close enough” is not close enough
Why “FDA cleared” language keeps confusing consumers
The January 6, 2026 document is a guidance describing enforcement discretion for certain general wellness products. That is fundamentally different from an FDA authorization for a medical device feature.
The FDA’s own language reinforces the difference. The agency says blood pressure measuring/estimating devices do not fall within the general wellness policy because they are not solely for general wellness and are not low risk. The September 2025 safety communication is essentially a reminder that a wearable can be “wellness-friendly” in one feature and potentially unlawful—or unsafe—in another.
This is also why doctors may push back even when a patient insists something is “FDA-approved.” If a device is operating under a wellness policy, that does not mean:
- the metric has clinical-grade accuracy
- the claim has been evaluated like a diagnostic device
- the results should drive treatment decisions
A consumer wearable can be responsibly designed and genuinely helpful while still being the wrong tool for blood pressure management. The FDA is, in effect, telling the market: you can innovate in wellness, but don’t smuggle medicine in through the back door.
“FDA ‘flexibility’ is not permission to medicalize every metric a sensor can produce.”
— — TheMurrow Editorial
What this means for companies—and why the stakes are bigger than marketing
Legal analyses have suggested the revised guidance provides more room for sensor-enabled wearables. That kind of room matters. It can affect product roadmaps, investor expectations, and how aggressively companies advertise features.
But blood pressure remains a flashing warning sign. The FDA’s enforcement posture—illustrated by the WHOOP warning letter and reinforced by the September 2025 safety communication—signals that BP estimation is not a “move fast and apologize later” feature.
For readers, this creates an uncomfortable but necessary question: if a company is willing to blur the line on blood pressure, what else might it blur? The issue isn’t that tech companies are uniquely untrustworthy. The issue is that market incentives reward bold claims, while clinical reality punishes them.
A real-world scenario: the risk of self-adjustment
Practical guidance for readers: how to use wearables without being misled
Use wearables for what they do best
- encourage sustained behavior change (movement, sleep routines)
- show trends rather than single-point “diagnoses”
- prompt questions you take to a clinician, rather than answer them alone
The FDA’s general wellness policy exists because not every health-adjacent feature needs to be regulated like a pacemaker. Wellness tools can still be meaningful without being clinical instruments.
Treat watch-based blood pressure claims as a high-risk zone
The AHA’s December 2025 statement adds a second layer: even where technologies show promise, many personal wearables are not yet proven accurate in real life, and standardized validation remains a work in progress.
Key Insight
A simple rule readers can remember
Use wearables without being misled
- ✓Use wearables to support habits (movement, sleep routines)
- ✓Focus on trends, not single readings
- ✓Bring questions to a clinician instead of self-diagnosing
- ✓Treat unauthorized BP estimation claims as a red flag
- ✓Avoid changing meds or delaying care based on wearable BP estimates
The deeper story: regulation is trying to keep up with psychology
Numbers shape choices. A wearable can make a person feel empowered, vigilant, even responsible. That’s often good. But it can also create a false sense of control—especially when the number has the emotional force of a diagnosis.
The FDA’s approach—broader discretion for low-risk wellness, sharper enforcement for blood pressure—recognizes a basic truth about risk: it’s not only about whether a sensor can be wrong; it’s about what people do when it is.
Wearables will keep moving toward medicine. Some will earn their place there. Until then, the most intelligent posture is neither techno-utopian nor dismissive. It is literate skepticism: use the tools, understand their category, and respect the difference between a wellness signal and a clinical measurement.
Frequently Asked Questions
Did the FDA “approve” new smartwatch health features in 2026?
No. On January 6, 2026, the FDA issued a nonbinding guidance on general wellness low-risk devices. Guidance describes when the agency may use enforcement discretion; it does not automatically approve, clear, or certify any wearable feature. It also does not guarantee accuracy or clinical usefulness of the metrics a device reports.
What is the FDA’s “General Wellness” policy, in plain English?
It’s an FDA compliance approach for certain products that make general wellness claims and are considered low risk. Under this policy, the FDA may choose not to enforce certain device requirements for qualifying products. It’s meant to allow consumer wellness tools to exist without being regulated like medical devices—so long as they don’t make medical claims.
Why is blood pressure treated differently from other wellness metrics?
Because blood pressure is closely tied to diagnosing and managing conditions like hypertension, and it can directly influence treatment decisions. The FDA warned on September 16, 2025 not to use unauthorized devices (including wearable software features) that claim to measure or estimate blood pressure, citing risks like stroke, heart attack, and kidney failure from incorrect results.
What did the FDA say about smartwatch or ring blood pressure features?
In its September 16, 2025 safety communication, the FDA told consumers and clinicians: do not use unauthorized devices for measuring blood pressure, including features on smartwatches and smart rings. The agency emphasized that inaccurate readings can lead to misdiagnosis, inappropriate treatment changes, and delayed care.
What was the WHOOP warning letter about?
On July 14, 2025, the FDA sent a warning letter to WHOOP, Inc., addressed to CEO Will Ahmed, regarding its Blood Pressure Insights feature. The FDA objected to marketing blood pressure estimations without authorization, arguing that systolic/diastolic estimation is “inherently associated” with diagnosing hypo- or hypertension—making it a medical device claim, not a general wellness claim.
Are cuffless blood pressure wearables accurate enough for diagnosis?
Not reliably, according to the American Heart Association. In a December 2025 scientific statement, the AHA said cuffless technologies show promise, but many personal wearables have not been proven accurate or reliable in real-world conditions like exercise, sleep, daily activity, and after taking medications that affect blood pressure. The AHA called for more research and standardized validation before using cuffless BP to diagnose.
